These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27557822)

  • 1. Clinical Effectiveness, Safety Profile, and Pharmacokinetics of Daptomycin in Pediatric Patients: A Systematic Review.
    Karageorgos SA; Miligkos M; Dakoutrou M; Tsioutis C
    J Pediatric Infect Dis Soc; 2016 Dec; 5(4):446-457. PubMed ID: 27557822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of daptomycin in a critically ill adolescent with vancomycin-resistant enterococcal endocarditis.
    Akins RL; Haase MR; Levy EN
    Pharmacotherapy; 2006 May; 26(5):694-8. PubMed ID: 16715610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of cSSTIs: the role of daptomycin.
    Garau J
    Curr Med Res Opin; 2006 Nov; 22(11):2079-87. PubMed ID: 17076967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daptomycin: a new drug class for the treatment of Gram-positive infections.
    Alder JD
    Drugs Today (Barc); 2005 Feb; 41(2):81-90. PubMed ID: 15821781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
    Rybak MJ
    Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of intravenous daptomycin in Japanese pediatric patients: Pharmacokinetic comparisons supporting dosing recommendations in Japanese pediatric patients.
    Ishii M; Orito Y; Shiomi M; Wrishko RE; Yoshitsugu H
    J Infect Chemother; 2023 Jun; 29(6):592-598. PubMed ID: 36868408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daptomycin.
    Heidary M; Khosravi AD; Khoshnood S; Nasiri MJ; Soleimani S; Goudarzi M
    J Antimicrob Chemother; 2018 Jan; 73(1):1-11. PubMed ID: 29059358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections.
    Abdel-Rahman SM; Benziger DP; Jacobs RF; Jafri HS; Hong EF; Kearns GL
    Pediatr Infect Dis J; 2008 Apr; 27(4):330-4. PubMed ID: 18316988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci.
    Cervera C; Castañeda X; Pericas JM; Del Río A; de la Maria CG; Mestres C; Falces C; Marco F; Moreno A; Miró JM
    Int J Antimicrob Agents; 2011 Nov; 38(5):365-70. PubMed ID: 21420835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Daptomycin in the treatment of Gram-positive infections in patients with chronic renal failure].
    Sarriá Cepeda C
    Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():38-42. PubMed ID: 22541974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daptomycin.
    Enoch DA; Bygott JM; Daly ML; Karas JA
    J Infect; 2007 Sep; 55(3):205-13. PubMed ID: 17629567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections.
    Kern WV
    Int J Clin Pract; 2006 Mar; 60(3):370-8. PubMed ID: 16494659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE.
    Seaton RA; Gonzalez-Ruiz A; Cleveland KO; Couch KA; Pathan R; Hamed K
    Ann Clin Microbiol Antimicrob; 2016 Mar; 15():18. PubMed ID: 26976128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria.
    Johnson A
    Future Microbiol; 2006 Oct; 1(3):255-65. PubMed ID: 17661638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Daptomycin, the first cydal antibiotic of a new class active against Gram positive pathogens].
    Stefani S; Esposito S
    Infez Med; 2006 Dec; 14(4):179-96. PubMed ID: 17380085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence.
    Falagas ME; Giannopoulou KP; Ntziora F; Vardakas KZ
    J Antimicrob Chemother; 2007 Jul; 60(1):7-19. PubMed ID: 17550889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daptomycin in bone and joint infections: a review of the literature.
    Rice DA; Mendez-Vigo L
    Arch Orthop Trauma Surg; 2009 Nov; 129(11):1495-504. PubMed ID: 18989686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections.
    Di Paolo A; Tascini C; Polillo M; Gemignani G; Nielsen EI; Bocci G; Karlsson MO; Menichetti F; Danesi R
    Int J Antimicrob Agents; 2013 Sep; 42(3):250-5. PubMed ID: 23891432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daptomycin is safe and effective for the treatment of gram-positive cocci infections in solid organ transplantation.
    Len O; Montejo M; Cervera C; Fariñas MC; Sabé N; Ramos A; Cordero E; Torre-Cisneros J; Martín-Dávila P; Azanza JR; Pahissa A; Gavaldà J;
    Transpl Infect Dis; 2014 Aug; 16(4):532-8. PubMed ID: 24834833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Daptomycin in the context of antimicrobial resistance in Gram-positive bacteria].
    Candel González FJ
    Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():10-6. PubMed ID: 22541970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.